S&P Equity Research downgrades Myriad Genetics (Nasdaq: MYGN) from Buy to Hold.

S&P analyst, P. Starsia, says, "Our downgrade ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE